| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
1 Hormel Institute, University of Minnesota, Austin, Minnesota, and 2 Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey
Caffeine is a major biologically active constituent in coffee and tea. Because caffeine has been reported to inhibit carcinogenesis in UVB-exposed mice, the cancer-preventing effect of caffeine has attracted considerable attention. In the present study, the effect of caffeine in quiescent (G0 phase) cells was investigated. Pretreatment with caffeine suppressed cell proliferation in a dose-dependent manner 36 h after addition of fetal bovine serum as a cell growth stimulator. Analysis by flow cytometry showed that caffeine suppressed cell cycle progression at the G0/G1 phase, i.e., 18 h after addition of fetal bovine serum, the percentages of cells in G0/G1 phase in 1 mM caffeine-treated cells and in caffeine-untreated cells were 61.7 and 29.0, respectively. The percentage of cells in G0/G1 phase at 0 h was 75.5. Caffeine inhibited phosphorylation of retinoblastoma protein at Ser780 and Ser807/Ser811, the sites where retinoblastoma protein has been reported to be phosphorylated by cyclin-dependent kinase 4 (cdk4). Furthermore, caffeine inhibited the activation of the cyclin D1-cdk4 complex in a dose-dependent manner. However this compound did not directly inhibit the activity of this complex. In addition, caffeine did not affect p16INK4 or p27Kip1 protein levels, but inhibited the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase 3ß. Our results showed that caffeine suppressed the progression of quiescent cells into the cell cycle. The inhibitory mechanism may be due to the inhibition of cell growth signal-induced activation of cdk4, which may be involved in the inhibition of carcinogenesis in vivo.
This article has been cited by other articles:
![]() |
T. Naganuma, S. Kuriyama, M. Kakizaki, T. Sone, N. Nakaya, K. Ohmori-Matsuda, Y. Nishino, A. Fukao, and I. Tsuji Coffee Consumption and the Risk of Oral, Pharyngeal, and Esophageal Cancers in Japan: The Miyagi Cohort Study Am. J. Epidemiol., December 15, 2008; 168(12): 1425 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Rogozin, K. W. Lee, N. J. Kang, H. Yu, M. Nomura, K.-I. Miyamoto, A. H. Conney, A. M. Bode, and Z. Dong Inhibitory effects of caffeine analogues on neoplastic transformation: structure-activity relationship Carcinogenesis, June 1, 2008; 29(6): 1228 - 1234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kotsopoulos, P. Ghadirian, A. El-Sohemy, H. T. Lynch, C. Snyder, M. Daly, S. Domchek, S. Randall, B. Karlan, P. Zhang, et al. The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 912 - 916. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |